TONIX Pharmaceuticals, Inc. Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment

NEW YORK--(BUSINESS WIRE)--Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, today reports that its new sublingual (under-the-tongue) formulation of its fibromyalgia (FM) drug TNX-102 reduces the production of a problematic metabolite, according to data from a recently-completed clinical trial.